HR 1266, the Combating Illicit Xylazine Act, adds xylazine - a veterinary sedative increasingly found in illicit drug mixtures - to Schedule III of the Controlled Substances Act, regulating its use and trafficking. It directly affects veterinarians, animal owners, and manufacturers by allowing xylazine to be legally dispensed for animal use under specific veterinary prescriptions, while prohibiting non-veterinary human use. The bill includes transition periods (60 days for practitioners, 1 year for labeling) to ease compliance for manufacturers and practitioners, and requires the DEA and FDA to expedite necessary applications. It also mandates two congressional reports on xylazine's illicit use and trafficking patterns, and directs the Sentencing Commission to review penalties for offenses involving xylazine.
The FORMULA Act of 2026 requires the U.S. Food and Drug Administration to set strict limits on contaminants in infant formula, including heavy metals, microplastics, and synthetic pesticides. Manufacturers must test their products to meet these new standards and keep records of their testing for at least two years after the formula's shelf life expires. The law also mandates that the FDA report annually to Congress on any violations and the progress made in reducing contaminant levels in the domestic supply chain. These regulations will take effect 180 days after the bill is signed into law.
The Judicial Integrity Act amends federal law to clarify which judges and Supreme Court justices must recuse themselves from cases involving personal financial interests. It requires that any exemptions from these conflict-of-interest rules be established through a formal regulation issued by the Judicial Conference of the United States, which must include public notice and a comment period. This change ensures that decisions about whether a financial interest is too small to matter are made transparently rather than through individual waivers. The bill directly affects all federal judges and Supreme Court justices by tightening the standards for when they can participate in cases where they have a financial stake.
The Justice is BLIND Act of 2026 requires federal judges, including justices, magistrate judges, and bankruptcy judges, along with their spouses and dependent children, to place specific financial investments into qualified blind trusts within 90 days of taking office or enactment. This rule applies to securities, commodities, and derivatives but excludes widely held mutual funds, U.S. Treasury bonds, and income earned by spouses or children from their own jobs. The bill also mandates that these judges publicly attest to the establishment of the trust or confirm they hold no covered financial interests, with these reports made available online. Additionally, the law prohibits judges from dissolving or controlling these trusts for 180 days after they leave their judicial positions to prevent immediate conflicts of interest.
The BRRRRT Act of 2026 restricts the U.S. Department of Defense from retiring, divesting, or storing A-10 aircraft in a way that reduces the total inventory below the level needed to sustain operations through fiscal year 2033. To comply, the Air Force must maintain a minimum fleet of 126 planes organized into specific units dedicated to close air support and combat search and rescue missions. The bill also mandates that the Air Force preserve retired aircraft in recoverable condition, prohibits using them for spare parts, and requires a detailed plan to restore any training or maintenance capacity that was cut in anticipation of retirement. Additionally, the legislation bars the removal of A-10 training functions at Davis-Monthan Air Force Base and Nellis Air Force Base unless specific conditions are met, while requiring the Air Force to submit regular reports on fleet sustainment and preservation efforts.
This bill expands the Freedom of Information Act to require federal courts to release specific records upon public request. It mandates the disclosure of attorney disciplinary actions, complaints against judges, meeting minutes, jury selection forms, and performance reports, while explicitly excluding information related to ongoing cases. The legislation also requires that released data be in a machine-readable format and authorizes funding to establish an office within the Administrative Office of the United States Courts to manage these new requirements.
HR 2913, the Ukraine Support Act, provides comprehensive U.S. support for Ukraine in response to Russia's invasion. The bill authorizes security assistance including lend-lease authority for military equipment, establishes a Ukraine Reconstruction Trust Fund for economic recovery, and imposes new sanctions targeting Russian financial institutions, oil companies, and government officials. It also includes provisions to counter Russian disinformation, support Radio Free Europe, and address the kidnapping of Ukrainian children. The legislation directly affects U.S. foreign policy, Ukraine's defense capabilities, and Russia's access to international financial systems. The act aims to strengthen Ukraine's sovereignty while holding Russia accountable for its actions.
The IBOGAINE Act aims to accelerate the development and approval of ibogaine and similar compounds for treating addiction, trauma, and serious mental illnesses by modifying federal drug laws. It creates a new voucher system that grants sponsors of breakthrough mental health drugs priority review by the FDA, while also establishing special registration rules to allow physicians to legally administer Schedule I substances to eligible patients under the "right to try" law. The legislation further directs the Department of Veterans Affairs to create a dedicated senior official and workforce plan for emerging therapies, mandates timely rescheduling of ibogaine from Schedule I to Schedule II, and requires federal agencies to share clinical trial data to speed up the approval process.
The Save MEDICARE Act of 2026 aims to improve the Medicare Advantage program by starting in 2028 with several changes to how health plans are paid and monitored. It requires the government to exclude diagnoses from chart reviews when calculating payments to prevent plans from inflating costs based on questionable data. The bill also speeds up audits and appeals to ensure faster resolution of coding disputes and introduces a new penalty system to recover overpayments from plans. Additionally, the law allows states to enforce Medicare rules within their borders and bans financial incentives for doctors based on how they code patient records. Finally, it establishes a mechanism for the Department of Veterans Affairs to recover costs when Medicare Advantage plans cover care that should have been paid for by the VA.
This resolution honors the life and legacy of the late Senator Lindsey Olin Graham from South Carolina. It formally acknowledges his extensive career in the military, state government, and Congress, noting his service as a Senator and his roles as Chairman of the Judiciary and Budget committees. The Senate expresses its sorrow over his death and requests that this tribute be shared with the House of Representatives and Graham's family.
This resolution expresses the House of Representatives' support for maintaining equity, diversity, and inclusion in federally funded health research to improve scientific quality and patient outcomes. It opposes proposed administrative rules that would allow political appointees to override peer reviews, restrict international collaborations, and ban funding for studies on diversity and health disparities. The text highlights historical data showing that excluding women and people of color from research has led to medical gaps, such as inaccurate diagnostic tools for Black patients and delayed diagnoses for women with heart disease. Ultimately, the bill urges the administration to preserve the current science-based peer review system and remove barriers that prevent underserved communities from benefiting from medical advancements.
The Cannabis Administration and Opportunity Act fundamentally changes federal law by removing marijuana from the Controlled Substances Act, effectively decriminalizing it at the federal level and allowing states to regulate their own cannabis markets without federal interference. To manage this new landscape, the bill creates a new federal agency called the Alcohol, Tobacco, and Cannabis Tax and Trade Bureau to oversee licensing, collect taxes, and prevent illicit trade, while also establishing a new Center for Cannabis Products within the FDA to regulate safety and labeling. The legislation includes significant restorative justice measures, such as automatically expunging federal cannabis convictions and prohibiting discrimination against individuals with such records in areas like immigration, security clearances, and access to federal benefits. Additionally, the bill provides billions of dollars in funding to support research into the health effects of cannabis, expand access to financial services for legitimate cannabis businesses, and assist communities and individuals harmed by past prohibition enforcement.
